Mark Kidd

List of Publications by Year
in descending order

68 papers	8,345 citations	101384 36 h-index	102304 66 g-index
68 all docs	68 docs citations	68 times ranked	7082 citing authors

#	Article	IF	Citations
1	A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 2003, 97, 934-959.	2.0	2,478
2	The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America, 2011, 40, 1-18.	1.2	715
3	Neuroendocrine tumor epidemiology. Cancer, 2008, 113, 2655-2664.	2.0	464
4	Bronchopulmonary neuroendocrine tumors. Cancer, 2008, 113, 5-21.	2.0	439
5	Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncology, The, 2014, 15, e8-e21.	5.1	413
6	Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 5-19.	3.3	357
7	Chromogranin Aâ€"Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease. Annals of Surgical Oncology, 2010, 17, 2427-2443.	0.7	325
8	Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. American Journal of Physiology - Renal Physiology, 2008, 295, G260-G272.	1.6	193
9	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nature Genetics, 2018, 50, 979-989.	9.4	168
10	Neuroendocrine tumors of the diffuse neuroendocrine system. Current Opinion in Oncology, 2008, 20, 1-12.	1.1	140
11	The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood. PLoS ONE, 2013, 8, e63364.	1.1	139
12	Gastrointestinal Carcinoids: The Evolution of Diagnostic Strategies. Journal of Clinical Gastroenterology, 2006, 40, 572-582.	1.1	110
13	The Role of Genetic Markersâ€" NAP1L1, MAGE-D2, and MTA1â€"in Defining Small-Intestinal Carcinoid Neoplasia. Annals of Surgical Oncology, 2006, 13, 253-262.	0.7	108
14	Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1437-E1445.	1.8	103
15	Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer. Seminars in Nuclear Medicine, 2016, 46, 225-238.	2.5	97
16	A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	93
17	The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?. Neuroendocrinology, 2015, 101, 1-17.	1.2	92
18	The NETest. Endocrinology and Metabolism Clinics of North America, 2018, 47, 485-504.	1.2	91

#	Article	IF	Citations
19	Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery, 2016, 159, 336-347.	1.0	90
20	NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive. Neuroendocrinology, 2017, 104, 170-182.	1.2	87
21	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocrine Connections, 2016, 5, 174-187.	0.8	83
22	Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocrine-Related Cancer, 2015, 22, 561-575.	1.6	80
23	A Nomogram to Assess Small-Intestinal Neuroendocrine Tumor (â€˜Carcinoidâ€™) Survival. Neuroendocrinology, 2010, 92, 143-157.	1.2	75
24	Neuroendocrine Tumor Biomarkers: Current Status and Perspectives. Neuroendocrinology, 2014, 100, 265-277.	1.2	75
25	Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer, 2005, 103, 229-236.	2.0	74
26	Neuroendocrine Neoplasms of the Small Bowel and Pancreas. Neuroendocrinology, 2020, 110, 444-476.	1.2	70
27	GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for real-time PCR. Physiological Genomics, 2007, 30, 363-370.	1.0	64
28	A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology, 2018, 107, 73-90.	1.2	61
29	Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer, 2008, 113, 690-700.	2.0	56
30	Chromogranin A. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 28-37.	1.2	55
31	Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors. Thoracic Surgery Clinics, 2014, 24, 333-349.	0.4	52
32	A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases. Epigenetics and Chromatin, 2014, 7, 15.	1.8	50
33	Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. Journal of Molecular Endocrinology, 2007, 38, 181-192.	1.1	47
34	Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nature Reviews Clinical Oncology, 2016, 13, 691-705.	12.5	47
35	Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factorâ€“Î²1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1. Cancer, 2007, 109, 2420-2431.	2.0	46
36	A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors. Endocrine Connections, 2014, 3, 215-223.	0.8	42

#	Article	IF	Citations
37	The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Advances in Medical Sciences, 2020, 65, 18-29.	0.9	38
38	Myeloid neoplasms after chemotherapy and PRRT: myth and reality. Endocrine-Related Cancer, 2016, 23, C1-C7.	1.6	36
39	Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility. Clinical Chemistry and Laboratory Medicine, 2014, 52, 419-429.	1.4	35
40	The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progressionâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 631-639.	0.6	35
41	The pivotal role of John S. Edkins in the discovery of gastrin. World Journal of Surgery, 1997, 21, 226-234.	0.8	34
42	Utility of molecular genetic signatures in the delineation of gastric neoplasia. Cancer, 2006, 106, 1480-1488.	2.0	34
43	Delineation of the Chemomechanosensory Regulation of Gastrin Secretion Using Pure Rodent G Cells. Gastroenterology, 2009, 137, 231-241.e10.	0.6	33
44	Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors. BMC Genomics, 2014, 15, 595.	1.2	33
45	Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. Cancer, 2008, 112, 1404-1414.	2.0	32
46	Q RT-PCR Detection of Chromogranin A. Annals of Surgery, 2006, 243, 273-280.	2.1	31
47	Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve followâ€up after curative surgical resection of wellâ€differentiated pancreatic neuroendocrine tumors. Journal of Surgical Oncology, 2018, 118, 37-48.	0.8	30
48	An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis. Neuroendocrinology, 2020, 110, 198-216.	1.2	28
49	Gastric Carcinoids (Neuroendocrine Neoplasms). Gastroenterology Clinics of North America, 2013, 42, 381-397.	1.0	27
50	Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems. Endocrine Connections, 2017, 6, 71-81.	0.8	25
51	Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). Annals of Surgical Oncology, 2021, 28, 7506-7517.	0.7	25
52	Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. Annals of Surgery, 2021, 274, 481-490.	2.1	22
53	A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis. Oncotarget, 2018, 9, 7182-7196.	0.8	20
54	PRRT: Defining the Paradigm Shift to Achieve Standardization and Individualization. Journal of Nuclear Medicine, 2014, 55, 1753-1756.	2.8	19

#	Article	IF	Citations
55	Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis. PLoS ONE, 2019, 14, e0218592.	1.1	17
56	Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms. Neuroendocrinology, 2020, 110, 185-197.	1.2	14
57	Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest. Neuroendocrinology, 2021, 111, 490-504.	1.2	14
58	Management of Gastric Carcinoids (Neuroendocrine Neoplasms). Current Gastroenterology Reports, 2012, 14, 467-472.	1.1	13
59	Van Swieten and the Renaissance of the Vienna Medical School. World Journal of Surgery, 2001, 25, 444-450.	0.8	12
60	GNA15 expression in small intestinal neuroendocrine neoplasia: Functional and signalling pathway analyses. Cellular Signalling, 2015, 27, 899-907.	1.7	12
61	Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms. Journal of Thoracic Disease, 2017, 9, S1458-S1473.	0.6	11
62	A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy. Endocrine-Related Cancer, 2021, 28, 731-744.	1.6	9
63	Small intestinal neuroendocrine cell pathobiology: â€˜carcinoidâ€™ tumors. Current Opinion in Oncology, 2011, 23, 45-52.	1.1	8
64	Minichromosome Maintenance Expression Defines Slow-Growing Gastroenteropancreatic Neuroendocrine Neoplasms. Translational Oncology, 2016, 9, 411-418.	1.7	6
65	A Historical Appreciation of Bronchopulmonary Neuroendocrine Neoplasia. Thoracic Surgery Clinics, 2014, 24, 235-255.	0.4	5
66	The Use of Deep Learning and Neural Networks in Imaging: Welcome to the New Mathematical Milieu of Medicine. Neuroendocrinology, 2020, 110, 322-327.	1.2	5
67	The History of the Pancreas. , 0, , 7-41.		3
68	Peptide radio receptor therapy: The huff and puff strategy of neuroendocrine disease management. Current Opinion in Endocrine and Metabolic Research, 2021, 19, 52-60.	0.6	0